Hubei Enoray Biopharmaceutical Co., Ltd., an API subsidiary of Chase Sun, was successfully granted a patent "Detection and Analysis Method of Heparan Sulfate Impurities in Heparin Sodium". Using this novel method, it will be able to keep optimizing the detection of impurities in heparin sodium and further improve the quality of related APIs.
Enoray has been focusing on the research, development and production of heparin related polysaccharide-based medicines since 2010 and has formed its core competency in heparin extraction and fractionated low molecular weight heparin preparation technology. It has a complete industrial chain including pork small intestine processing, mucosal heparin extraction, heparin APIs, and graded low molecular weight heparin APIs. Its products are sold in many territories including North America, South America, Europ and Oceania.
